Weiss R B, Stablein D M, Muggia F M, Einhorn L H, Golbey R B, DeWys W D
Section of Medical Oncology, Walter Reed Army Medical Center, Washington, DC 20307.
Cancer. 1988 Jul 1;62(1):18-23. doi: 10.1002/1097-0142(19880701)62:1<18::aid-cncr2820620105>3.0.co;2-q.
The Testicular Cancer Intergroup Study was initiated to evaluate the efficacy of adjuvant chemotherapy in Stage II and salvage therapy in Stage I nonseminomatous testicular carcinoma. Chemotherapy regimens of cisplatin, vinblastine, and bleomycin (PVB) or the same drugs plus cyclophosphamide and dactinomycin (VAB) were used at institution or cooperative group preference. A comparison of the toxicities of these two regimens shows that VAB caused significantly more mucosal, dermatologic, and otologic toxicity than PVB, and PVB caused more leucopenia. Both regimens were equally effective in controlling cancer. Either regimen could be used as chemotherapy in testicular cancer, and the decision about which one to use could be based on their differences in toxicity and degree of patient convenience.
睾丸癌协作组研究旨在评估辅助化疗对Ⅱ期睾丸癌的疗效以及挽救性治疗对Ⅰ期非精原细胞瘤性睾丸癌的疗效。顺铂、长春碱和博来霉素（PVB）化疗方案或相同药物加环磷酰胺和放线菌素D（VAB）化疗方案的选择取决于各机构或协作组的偏好。对这两种化疗方案毒性的比较表明，VAB引起的黏膜、皮肤和耳毒性明显高于PVB，而PVB引起的白细胞减少更多。两种方案在控制癌症方面同样有效。两种方案均可作为睾丸癌的化疗方案，具体使用哪种方案可根据其毒性差异和患者便利程度来决定。
